The medicine is commonly used across conditions presenting with acute episodes and those involving chronic discomfort. Ultrafen (Diclofenac) is primarily applied in addressing symptoms related to inflammatory or irritative states and may assist with short-term symptomatic assistance. It plays a role in managing symptoms that create noticeable physiological strain and helps support the easing of the overall symptom load.

Ultrafen is applicable within clinical settings that involve acute or disruptive symptom patterns, including intense episodes of migraine headaches, acute gout, and painful dysmenorrhea. It may be part of symptomatic management for long-term conditions such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. The overall benefit is focused on physical comfort:

“The symptomatic support offered by the medicine supports the patient during difficult episodes by easing distress and may assist with functional stability during periods of heightened discomfort.”

---

Managing Symptom Domains

Applied across domains where additional symptomatic support is needed, the medicine helps manage symptoms related to physical discomfort and stiffness, and may assist with supporting functional stability in conditions where symptoms may intensify temporarily. It is used for managing symptoms associated with acute or episodic changes, such as sprains, strains, or post-procedure discomfort, helping patients cope more steadily.

Quick Fact: Symptomatic Relief
The medicine is commonly used to help with symptoms related to physical discomfort and associated swelling, assisting with functional stability.

Regulatory References

1. NIH MedlinePlus overview on Diclofenac

Eligibility Scope

Classification	Population Restriction
Contraindicated	Patients with established congestive heart failure (NYHA Class II–IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
	Individuals with active gastrointestinal bleeding, peptic ulceration, or a history of allergic reactions to aspirin or other NSAIDs.
	Pregnant women at 30 weeks gestation and later (third trimester) due to risk of fetal complications.
Conditional Use	Older adults (ge 65 years) are at greater risk for serious cardiovascular, renal, and GI events; use requires particular caution.
	Patients with uncontrolled hypertension, mild-to-moderate renal or hepatic impairment, or other cardiovascular risk factors must be treated after careful consideration.
Not Established	Safety and efficacy have not been established for all systemic forms in children and adolescents below specific age thresholds (e.g., typically under 14 years).

Connection to the Overall Eligibility Profile

Official regulatory documents classify numerous groups as contraindicated, primarily due to the high risks associated with pre-existing cardiovascular conditions, severe organ impairment, and active GI disease. Use is explicitly prohibited in the final trimester of pregnancy. For all other eligible groups, use is restricted to the lowest effective dose for the shortest duration possible, particularly for older adults and those with underlying risk factors.

Interactions with other medicines and products

Official regulatory documents classify interactions with Ultrafen (Diclofenac) based on their mechanism and the resulting constraints on co-administration.

Classification	Official Regulatory Documentation Statement
Contraindicated Combinations	The medicine is contraindicated for use in the perioperative pain setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including those containing Aspirin (for non-cardio protective uses), is officially discouraged due to heightened risk of serious gastrointestinal events.
Pharmacokinetic Interactions	Co-administration with Voriconazole (a potent inhibitor of CYP2C9 and other enzymes) is documented to increase the maximum plasma concentration ( C max) and Area Under the Curve ( AUC) of Diclofenac, a metabolic interaction. Medicines that are eliminated by the kidneys, such as Lithium and Digoxin, may have increased serum concentrations upon co-administration.
Pharmacodynamic Interactions	The combination with Anticoagulants (e.g., Warfarin), Antiplatelet agents, or Selective Serotonin Reuptake Inhibitors (SSRIs) increases the documented risk of bleeding. Ultrafen may also diminish the antihypertensive and natriuretic effects of ACE Inhibitors, ARBs, and Diuretics.
Administration Constraints	Ingestion of alcohol with this medicine is officially cited as increasing the risk of serious gastrointestinal mucosal bleeding and ulceration. For certain oral formulations, administration with food may lead to a reduction in effectiveness.
Population-Specific Note	The interaction involving the potential deterioration of renal function with ACE Inhibitors and ARBs is cited as being of higher risk in the elderly or those with volume depletion or pre-existing renal impairment.

Regulatory warnings establish that the drug's interaction structure is defined by additive pharmacodynamic effects that compound existing risks and specific pharmacokinetic alterations that change drug or co-administered drug exposure.

How Ultrafen Works

---

Enzyme-Mediated Signal Suppression

Ultrafen's mechanism is anchored in enzyme-mediated signaling, specifically by functioning as an inhibitor of cyclooxygenase (COX) enzymes. This molecular interaction competitively blocks the active site of COX, preventing the crucial conversion of arachidonic acid into eicosanoids. By limiting the initial enzymatic steps, the drug achieves a robust reduction in the biosynthesis of downstream inflammatory mediators.

---

Modulation of Prostaglandin Synthesis

The key pharmacodynamic effect is a reduction in the total synthesis of prostaglandins (PGs), which are lipid signaling molecules essential for local physiological responses. The subsequent suppression of PGs alters the overall magnitude of mediator-driven cellular signaling. This pathway modification leads to a diminished output of signals contributing to localized fluid accumulation.

---

Influence on Nociception and Thermal Pathways

Beyond local effects, Ultrafen engages mechanisms that modulate processes in the central nervous system. By disrupting the prostaglandin cascade, the drug influences the signaling pathways involved in nociception. Additionally, it affects prostaglandin-mediated activity in the hypothalamic thermoregulatory center, resulting in a modulation of the thermal set-point elevation.

The administration of Ultrafen (Diclofenac) follows specific routes, dosage ranges, and procedural instructions for its use. The medicine is available for administration via multiple routes, including oral forms, topical application, and parenteral methods such as intravenous (IV) or intramuscular (IM) injection, in addition to rectal suppositories.

Dosing is highly form- and indication-specific. For chronic management, such as in Osteoarthritis, the typical oral regimen is a total daily dose between 100 mg and 150 mg, often administered in divided doses. Extended-Release (ER) formulations are typically prescribed as a single 100 mg dose once daily. A core principle of use is employing the lowest effective dosage for the shortest duration possible consistent with treatment goals.

Administration Rules

Entity	General Instruction
Oral Intake	Delayed-Release (DR) and Extended-Release (ER) tablets/capsules must be swallowed whole and not crushed, broken, or chewed.
Timing	Oral forms may be taken with or without food.
Parenteral Use	IM administration is generally time-limited (e.g., often not exceeding two days); IV administration requires the patient to be well hydrated prior to delivery.
Form Non-Equivalence	Different salt forms and release types (IR vs. ER) are not bioequivalent and should not be interchanged.

Specific products, such as the powder for oral solution, carry instructions to mix the packet with 1 to 2 ounces of water and consume immediately. Furthermore, treatment may be initiated at the lowest dose for patients with established hepatic impairment.

Research Evidence / Overview of Studies for Ultrafen

---

Evidence for Chronic Inflammatory Conditions (Osteoarthritis)

Research exploring Ultrafen in studies of chronic conditions such as osteoarthritis includes numerous Randomized Controlled Trials (RCTs) and systematic reviews. These studies evaluated outcomes related to physical discomfort and changes in outcomes reflecting daily functioning using patient-reported scores. Both oral and topical formulations were examined.

In these trials, researchers reported how measured outcomes changed in the observed populations when compared against a placebo or other active treatments. Research findings describe patterns observed in the measured outcomes related to physical discomfort and physical function in the studies. However, scientists have noted that high heterogeneity (meaning the findings varied greatly) across different studies complicates the interpretation of combined data. Long-term outcomes are not fully established, as many foundational trials had follow-up durations that were limited to a few weeks or months.

---

Evidence for Acute and Episodic Pain States (Migraine and Dysmenorrhea)

Research for conditions characterized by episodic or acute manifestations, such as migraine headaches, primarily uses highly focused, short-term RCTs. These studies evaluated outcomes related to episodic changes. Key metrics monitored included the percentage of patients who became pain-free at 2 hours and the rate of symptoms recurring within the first 48 hours. A key research limitation is that the primary focus on the 2-hour endpoint provides limited information for long-term outcomes or repeated use patterns. Data regarding long-term response remains insufficient.

---

Evidence in Specific Patient Populations and Uncertainties

Most core clinical trials for Ultrafen were conducted in general adult populations, meaning results apply only to the populations studied. Evidence is limited for certain groups, such as children. Studies focusing on patients with comorbid conditions are often found in larger, post-marketing observational settings, which provide evidence derived from settings with varying symptom burdens compared to the controlled conditions of an RCT. Scientific literature highlights that subgroup findings are uncertain for specific populations, and comparative evidence is lacking for certain formulations against all current treatments.

Common questions about Ultrafen (FAQ)

Q: Is Ultrafen a drug for acute or chronic conditions?

A: Official regulatory documents indicate that the medicine is approved for treating conditions that are both acute (short-term, like pain and migraine attacks) and chronic (long-term, like osteoarthritis and rheumatoid arthritis).

Q: What forms is Ultrafen available in?

A: Ultrafen's active ingredient, Diclofenac, is available in multiple forms. These include various oral tablets and capsules, a powder for oral solution, topical gel, and solutions for injection, allowing for different routes of administration.

Q: How long does the effect of a single dose of Ultrafen last?

A: Scientific literature on the drug's activity indicates that the medicine has a short terminal elimination half-life, typically cited as approximately 1 to 2 hours. This value reflects how quickly the body processes and removes the medicine.

Q: Can Ultrafen be used during pregnancy or breastfeeding?

A: Official warnings advise against using the medicine from 20 weeks gestation and later due to potential fetal risk. Regarding breastfeeding, official sources state that the medicine passes into breast milk in small amounts, and some experts consider its use acceptable.

Q: What did the major clinical studies on Ultrafen demonstrate?

A: Clinical trials demonstrate that the medicine is comparable in effectiveness to several other NSAIDs. Studies primarily focus on improving function and reducing physical discomfort in populations with conditions such as osteoarthritis and rheumatoid arthritis.

Q: What type of studies support the described benefits of Ultrafen?

A: The described benefits of Ultrafen are grounded in evidence from formal clinical studies. These include various Randomized Controlled Trials (RCTs) and systematic reviews conducted across the studied adult populations.

Q: Is it normal to have mild headaches when starting Ultrafen?

A: Headache is one of the adverse reactions that has been documented in post-marketing reports or in clinical studies for the medicine. The safety profile also includes documented effects on the Nervous System.

Q: What is the main goal of treatment with Ultrafen?

A: The general purpose of the medicine is to provide relief from discomfort. It achieves this by exerting its three core physiological actions: anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing).

Q: Does Ultrafen have a generic version available?

A: The active ingredient in Ultrafen, Diclofenac, is widely available in lower-cost generic versions and is generally covered by most prescription drug plans.

Q: Is Ultrafen an antibiotic?

A: No, Ultrafen is not an antibiotic. It belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) pharmacological class, meaning it works by reducing inflammation and pain signals in the body.

Q: Is Ultrafen classified as a controlled substance?

A: No, the medicine is an NSAID and is not classified as a controlled substance under the U.S. Controlled Substances Act or equivalent international regulatory frameworks.

Q: What are the most common side effects reported for Ultrafen in studies?

A: Official labeling documents indicate that the most frequently reported adverse reactions, occurring in approximately 1% to 10% of patients, are Gastrointestinal (GI) reactions. These include abdominal pain, constipation, diarrhea, indigestion, heartburn, and nausea.

Q: Has Ultrafen been linked to any serious liver problems?

A: Official warnings state that the medicine is associated with a risk of liver damage (hepatotoxicity). Significant elevations in liver enzymes have been documented in studies, which is why monitoring may be necessary.

Q: Does Ultrafen cause changes in appetite or weight?

A: Certain official reports have documented changes in weight, such as unusually fast weight gain due to fluid retention or swelling. These changes can be signs of potentially serious adverse events.

Q: Can people with high blood pressure use Ultrafen?

A: Official labeling states that the medicine can cause an increase in blood pressure and may diminish the effects of blood pressure medications. Use requires careful consideration, especially for patients with uncontrolled hypertension.

Q: Is Ultrafen approved for use in children?

A: Official documents state that safety and efficacy have not been established for all systemic forms in general pediatric populations. Certain formulations have been studied for specific inflammatory conditions in children.

Q: Can seniors or elderly patients take Ultrafen?

A: Yes, but official warnings state that older adults are at a greater risk for serious GI and cardiovascular adverse events. Due to this increased risk, use requires particular caution.

Q: Is Ultrafen considered an addictive drug?

A: No, the medicine is classified as an NSAID. It is not classified as an addictive or controlled substance by regulatory agencies.

Q: Why do some people report feeling restless or nervous after taking Ultrafen?

A: The safety profile documents adverse effects on the Nervous System. Restlessness or nervousness are among the adverse reactions that have been reported through various clinical studies and post-marketing surveillance.

Q: Does Ultrafen have a known effect on laboratory test results?

A: The medicine is documented to potentially affect several lab values, including liver enzyme levels. It may also increase the blood concentrations of other co-administered drugs like Lithium, which often requires monitoring.

Q: Can Ultrafen cause light sensitivity?

A: Official documents indicate that photosensitivity (increased sensitivity to sunlight or artificial UV light) is one of the rare, severe skin reactions that has been documented in connection with the medicine.

Q: Are there any special monitoring requirements (like blood tests) for long-term use of Ultrafen?

A: Long-term use requires monitoring due to the risks to the GI system, kidneys, and liver. This monitoring can involve regular checks of blood pressure, kidney function, and liver enzymes.

Q: What foods or supplements should be avoided while using Ultrafen?

A: Official warnings state the medicine should not be taken with alcohol or other NSAIDs. Furthermore, some sources advise caution with specific supplements like ginkgo biloba and ginseng due to documented interaction risks.

Q: Is it safe to combine Ultrafen with herbal teas?

A: Safety data is limited for most complementary medicines and herbal teas. Since these are not tested in the same way as prescription drugs, their potential for interaction remains uncertain.

Q: Is there a difference in how Ultrafen works if taken with food?

A: Yes, official administration guidelines indicate that for certain forms, such as Delayed-Release (DR) and Extended-Release (ER), administration with food may lead to a reduction in the effectiveness or absorption of the medicine.

Q: What pre-existing conditions make Ultrafen use risky?

A: Use is classified as risky for patients with pre-existing conditions such as heart disease, uncontrolled hypertension, severe kidney or liver impairment, active GI bleeding, or a history of allergic reactions to aspirin/NSAIDs.

Q: What is the half-life of Ultrafen?

A: Scientific literature indicates that the medicine has a short terminal elimination half-life, typically cited as approximately 1 to 2 hours. This refers to the time it takes for half of the drug to be eliminated from the body.

Q: What is the maximum number of days Ultrafen is typically prescribed for?

A: The guiding principle for all use, according to regulatory documents, is to take the lowest effective dosage for the shortest duration possible. For specific short-term needs, some uses (like intramuscular injection) are officially time-limited, often not exceeding two days.

Q: Can I take Ultrafen for a headache?

A: Specific formulations, such as the powder for oral solution, are officially approved and used to treat an acute migraine headache attack. The drug is designed to address the pain and inflammation components of headaches.

Q: Why is Ultrafen sometimes prescribed for different conditions?

A: The medicine is formally approved for the treatment of multiple different conditions. This includes chronic inflammatory conditions like osteoarthritis and rheumatoid arthritis, as well as acute pain conditions like migraine headache attacks.

How to Store and Dispose of Ultrafen

Ultrafen (Diclofenac) must be stored under specific conditions to maintain its stability, as defined by regulatory labeling.

---

Storage Requirements

• Temperature: Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Do not freeze the medicine and protect from heat.
• Protection: The product must be stored in its original, tightly closed container and protected from light and moisture.
• Child Safety: Ultrafen must be kept out of the sight and reach of children and pets.

---

Disposal Instructions

Dispose of unused or expired Ultrafen according to national and local regulations. Use an official drug take-back program when available. If take-back is unavailable, the product may be mixed with an undesirable substance, sealed, and placed in the household trash. Do not flush medicines down the toilet unless explicitly instructed by the labeling.